Author(s):
Salsa Lina Agustin, Tri Widiandani, Suko Hardjono, Bambang Tri Purwanto
Email(s):
tri-w@ff.unair.ac.id
DOI:
10.52711/0974-360X.2022.00779 
Address:
Salsa Lina Agustin1, Tri Widiandani2*, Suko Hardjono2, Bambang Tri Purwanto2
1Undergraduate Student, Faculty of Pharmacy, Universitas Airlangga, Mulyorejo, Surabaya 60115, Indonesia
2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Mulyorejo, Surabaya 60115, Indonesia
*Corresponding Author
Published In:
Volume - 15,
Issue - 10,
Year - 2022
ABSTRACT:
Pinostrobin is a compound with potential anti-breast cancer activity, but its activity is lower than the drugs used clinically. Modifying pinostrobin to form 9 acyl pinostrobin derivatives (AP1-AP9) is a method that changes physicochemical properties to affect the activity and ADMET properties. This study aims to predict the anti-breast cancer activity of pinostrobin and acyl pinostrobin derivatives against HER-2 receptor by molecular docking, obtain the most influential descriptor by QSAR study, and predict ADMET properties of these compounds. The molecular docking was using MVD on the HER-2 receptor (5JEB.pdb). The parameters observed were the Rerank Score (RS) and the amino acid residues. The physicochemical properties (logP, total energy, and molecular weight) for the QSAR study were determined using Chem Draw and Chem 3D. The QSAR study was carried out using SPSS. Prediction of ADMET properties was determined using the pkCSM. The molecular docking result showed that all acyl pinostrobin derivatives have a lower RS than pinostrobin. The lowest RS was indicated by pinostrobin nonanoate (AP8) with a value = -108,156 kcal/mol. The influential parameters in the QSAR study were the logP and MW. The results of this study also showed that the ADME properties of acyl pinostrobin derivatives were mainly better than pinostrobin, and all derivatives were also less toxic than pinostrobin. These results indicate that acyl pinostrobin derivatives, especially pinostrobin nonanoate (AP8), can be further synthesized as anti-breast cancer by considering the QSAR study's best equation.
Cite this article:
Salsa Lina Agustin, Tri Widiandani, Suko Hardjono, Bambang Tri Purwanto. QSAR of Acyl pinostrobin derivatives as Anti-breast cancer against HER-2 receptor and their ADMET properties based on in silico Study. Research Journal of Pharmacy and Technology 2022; 15(10):4641-8. doi: 10.52711/0974-360X.2022.00779
Cite(Electronic):
Salsa Lina Agustin, Tri Widiandani, Suko Hardjono, Bambang Tri Purwanto. QSAR of Acyl pinostrobin derivatives as Anti-breast cancer against HER-2 receptor and their ADMET properties based on in silico Study. Research Journal of Pharmacy and Technology 2022; 15(10):4641-8. doi: 10.52711/0974-360X.2022.00779 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-10-52
REFERENCES:
1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer. 2020.Available on https://gco.iarc.fr/today.
2. Ferlay J. Ervik M. Lam F. Colombet M. Mery L. Piñeros M. et al. Global Cancer Observatory: Cancer Tomorrow. Lyon: International Agency for Research on Cancer. 2020. Available onhttps://gco.iarc.fr/today.
3. Maeda H, Khatami M. Analyses of Repeated Failures in Cancer Therapy for Solid Tumors: Poor Tumor-Selective Drug Delivery, Low Therapeutic Efficacy and Unsustainable Costs. Clinical andTranslational Medicine. 2018 Mar 1;7(1):11.doi: 10.1186/s40169-018-0185-6
4. Chahyadi A, Hartati R, Wirasutisna KR, Elfahmi. Boesenbergia Pandurata Roxb., an Indonesian Medicinal Plant: Phytochemistry, Biological Activity, Plant Biotechnology. Procedia Chemistry. 2014;13:13-37.doi: 10.1016/j.proche.2014.12.003
5. Sukardiman, Charisma D, Plumeriastuti H, Arifianti L. Anticancer Effect of Pinostrobin from (Kaempferia pandurata Roxb) in Benzo(A)Pyrene – Induced Fibrosaroma in Mice. Planta Husada. 2014;2(2):44-6.
6. Atun S, Arianingrum R. Anticancer Activity of Bioactive Compounds from Kaempferia rotunda Rhizome against Human Breast Cancer. International Journal of Pharmacognosy and Phytochemical Research. 2015;7(2):262-9.
7. Ekowati J, Diyah NW, Nofianti KA, Hamid I, Siswandono. Molecular Docking of Ferulic Acid Derivatives on P2Y12 Receptor and their ADMET Prediction. Journal of Mathematical and Fundamental Sciences. 2018;50(2):203-19.
8. Kamath V, Pai A. Application of Molecular Descriptors in Modern Computational Drug Design –An Overview. Research Journal of Pharmacy and Technology. 2017; 10(9): 3237-41.doi: 10.5958/0974-360X.2017.00574.1
9. Poerwono H, Sasaki S, Hattori Y, Higashiyama K. Efficient Microwave-Assisted Prenylation of Pinostrobin and Biological Evaluation of Its Derivatives as Antitumor Agents. Bioorganic & Medicinal Chemistry Letter. 2010 Apr 1;20(7):2086-9.doi: 10.1016/j.bmcl.2010.02.068
10. Pratama M, Poerwono H, Siswandono S. Design and Molecular Docking of Novel 5-O-Benzoylpinostrobin Derivatives as Anti-Breast Cancer. Thai Journal of Pharmaceutical Sciences. 2019;43(4):201-12.
11. Hardjono S. Modifikasi Struktur 1-(benzoiloksi)urea dan Hubungan Kuantitatif Struktur-Aktivitas Sitotoksiknya. Disertasi Surabaya: Fakultas Farmasi Universitas Airlangga. 2012
12. Hardjono S. Siswandono. Purwanto. Darmanto W. Quantitative Structure-Cytotoxic Activity Relationship 1-(Benzoyloxy)urea and Its Derivatives. Current Drug Discovery Technology. 2016;13(2):101-8.
13. Pinzi L, Rastelli G. Molecular Docking: Shifting Paradigms in Drug Discovery. International Journal of Molecular Sciences. 2019 Sep 4;20(18):4331.doi: 10.3390/ijms20184331
14. Park KD, Lee SG, Kim SU, Kim SH, Sun WS, Cho SJ, Jeong DH. Anticancer Activity of 3-O-acyl and Alkyl-(-)-epicatechin Derivatives. Bioorganic & Medicinal Chemistry Letters. 2004;14:5189-92.doi: 10.1016/j.bmcl.2004.07.063
15. Hardjono S. Siswandono. Purwanto. Darmanto W. Quantitative Structure-Cytotoxic Activity Relationship 1-(Benzoyloxy)urea and Its Derivatives. Current Drug Discovery Technology. 2016;13(2):101-8.
16. Feng Y, Spezia M, Huang S, Yuan C, et al. Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis. Genes & Diseases. 2018;5(2):77-106.doi: 10.1016/j.gendis.2018.05.001
17. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-Positive Breast Cancer: Current Status and Future Perspectives. Natural Reviews Clinical Oncology. 2011 Nov 29;9(1):16-32. doi: 10.1038/nrclinonc.2011.177
18. Mehrgou A, Akouchekian M. The Importance of BRCA1 and BRCA2 Genes Mutations in Breast Cancer Development. Medical Journal of the Islamic Republic of Iran. 2016 May 15;30:369.
19. Abdel-Ilah L, Veljovic E, Gurbeta L,Badnjevic A.Applications of QSAR Study in Drug Design. International Journal of Engineering Research & Technology. 2017 June;6(6):582-7.
20. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104
21. Ekowati J, Diyah NW, Nofianti KA, Hamid I, Siswandono. Molecular Docking of Ferulic Acid Derivatives on P2Y12 Receptor and their ADMET Prediction. Journal of Mathematical and Fundamental Sciences. 2018;50(2):203-19.
22. Pagadala NS, Syed K, Tuszynski J. Software for Molecular Docking: A Review. Biophysical Review. 2017 Apr;9(2):91-102. doi: 10.1007/s12551-016-0247-1
23. Widiandani , Arifianti L, Siswandono. Docking, synthesis and cytotoxicity test on human breast cancer cell line (T47D) of N-(Allylcarbamothioyl)benzamide. International Journal of Pharmaceutical and Clinical Research. 2016;8(5)Suppl:372-76.
24. Widiandani T, Siswandono, Meiyanto E, Sulistyowaty MI, Purwanto BT, Hardjono S. New N-allylthiourea Derivatives, Synthesis, Molecular Docking and In Vitro Cytotoxicity Studies. Tropical Journal of Pharmaceutical Research. 2018 Aug;17(8): 1607-13. doi: 10.4314/tjpr.v17i8.20
25. Hardjono S, Widiandani T Purwanto BT, Nasyanka AL. Molecular Docking of N-Benzoyl-N’-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET prediction.Research Journal of Pharmacy and Technology. 2019 May;12(5):2160-66. doi: 10.5958/0974-360X.2019.00359.7
26. Hardjono S. Modifikasi Struktur 1-(benzoiloksi)urea dan Hubungan Kuantitatif Struktur-Aktivitas Sitotoksiknya. Disertasi Surabaya: Fakultas Farmasi Universitas Airlangga. 2012
27. Hardjono S. Siswandono. Purwanto. Darmanto W. Quantitative Structure-Cytotoxic Activity Relationship 1-(Benzoyloxy)urea and Its Derivatives. Current Drug Discovery Technology. 2016;13(2):101-8.
28. Siswandono, Widyowati R, Suryadi A. Widiandani T. Prismawan D. Molecular Modeling, Synthesis, and QSAR of 5-O-acylpinostrobin Derivatives as Promising Analgesic Agent. Rasayan Journal of Chemistry. 2020 Oct-Dec;13(4):2559-68. doi: 10.31788/ RJC.2020.1345749
29. Ekowati J, Diyah NW, Nofianti KA, Hamid I, Siswandono. Molecular Docking of Ferulic Acid Derivatives on P2Y12 Receptor and their ADMET Prediction. Journal of Mathematical and Fundamental Sciences. 2018;50(2):203-19.
30. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104
31. Hardjono S, Widiandani T Purwanto BT, Nasyanka AL. Molecular Docking of N-Benzoyl-N’-(4-fluorophenyl) thiourea Derivatives as Anticancer Drug Candidate and Their ADMET prediction.Research Journal of Pharmacy and Technology. 2019 May;12(5):2160-66. doi: 10.5958/0974-360X.2019.00359.7
32. Pratama MRF. Poerwono H. Siswodiharjo S. ADMET Properties of Novel 5-O-benzoylpinostrobin Derivatives. Journal of Basic and Clinical Physiology and Pharmacology. 2019 Dec;30(6): 2019-251. doi: 10.1515/jbcpp-2019-0251
33. Megantara S, Iwo MI, Levita J, Ibrahim S. Determination of Ligand Position in Aspartic Proteases by Correlating Tanimoto Coefficient and Binding Affinity with Root Mean Square Deviation. Journal of Applied Pharmaceuticals Science. 2016;6:125-9.
34. Castro-Alvarez A, Costa AM, Vilarrasa J. The Performance of Several Docking Programs at Reproducing Protein-Macrolide-Like Crystal Structure. Molecule. 2017;22:136.
35. Pagadala NS, Syed K, Tuszynski J. Software for Molecular Docking: A Review. Biophysical Review. 2017 Apr;9(2):91-102. doi: 10.1007/s12551-016-0247-1
36. Solomons TWG, Fryhle CB. Organic Chemistry 10th Edition. John Wiley and Sons Inc, New Jersey. 2011.
37. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104
38. Chander S, Tang C, Al-Maqtari HM, Jamalis J, Penta A, Hadda TB, Sirat HM, Zheng Y, Sankaranarayanan M.Synthesis and study of anti-HIV-1 RT activity of 5-benzoyl-4-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one derivatives. Bioorganic Chemistry. 2017;72:74-9.
39. Lipinski CA. Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. Journal of Pharmacological and Toxicological Methods. 2000;44:235-49.
40. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104
41. Singh SK, Singh S, Lillard JW Jr, Singh R. Drug delivery approaches for breast cancer. International Journal of Nanomedicine. 2017;12:6205-18. doi:10.2147/IJN.S140325
42. Liyanage PY, Hettiarachchi SD, Zhou Y, Ouhtit A, Seven ES, Oztan CY, Celik E, Leblanc RM. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer.2019;1871(2):419–433. doi:10.1016/j.bbcan.2019.04.006
43. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104
44. Diyah NW, Sondakh R. Hubungan Struktur dan Proses Metabolisme Obat.InKimia Medisinal, Edited by: Siswandono. Airlangga University Press, Surabaya. 2016; 2nd Edition.
45. Zanger UM, Schwab M.Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacology & Therapeutics. 2013;138(1):103-41. doi: 10.1016/j.pharmthera.2012.12.007
46. Lombardo F, Obach RS, Varma MV, Stringer R, Berellini G. Clearance Mechanism Assignment and Total Clearance Prediction in Human Based Upon in Silico Models. J Med Chem. 2014;57:4397–405.
47. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104
48. Badan Pengawas Obat dan Makanan. Peraturan Kepala Badan Pengawas Obat dan Makanan Nomor 7 Tahun 2014 Tentang Pedoman Uji Toksisitas Nonklinik Secara In Vivo. BPOM, Jakarta. 2014.
49. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry. 2015;58(9):4066-72.doi: 10.1021/acs.jmedchem.5b00104